The Board of Directors considered and approved the acquisition of equity shares representing up to 100% of the paid-up equity share capital of iSERA Biological Limited (an unlisted public ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
iSERA Lifesciences Limited (formerly Covidh Technologies) has approved acquisition of up to 100% equity stake in iSERA Biological Limited through a share swap arrangement. The company will issue 1,61,82,800 equity shares at Rs. 48.20 per share to acquire iSERA Biological Limited shareholders, making it a wholly-owned subsidiary. The swap ratio is 1:1 (one share of iSERA Lifesciences for every one share of iSERA Biological). Total consideration is Rs. 78 crore. The board also approved increasing authorised share capital from Rs. 11 crore to Rs. 25 crore, adopting new MOA/AOA aligned with Companies Act 2013, and enhancing investment limits to Rs. 1,000 crore. The target company achieved turnover of Rs. 18.36 crore in FY 2024-25 and operates in pharmaceuticals, biotechnology and life sciences. This is a related party transaction as promoters of the company are also shareholders of the target.
The acquisition consolidates iSERA Lifesciences' presence in the pharma and life sciences sector and creates a wholly-owned subsidiary. The 1:1 swap ratio at arm's length price suggests fair valuation. However, significant promoter shareholding increase (from ~41% to ~54%) through this related party transaction will substantially dilute public float and concentrate ownership.